文献速递炎症性肠病

用药全景研究:探索炎症性肠病诊断前10年的药物使用情况

Medication-Wide Study: Exploring Medication Use 10 Years Before a Diagnosis of Inflammatory Bowel Disease.
PubMed 文献 · Am J Gastroenterol · 2023-07-07

基于丹麦全国登记数据,纳入2005至2018年确诊的29219例炎症性肠病(IBD)患者并匹配292190例无IBD个体,比较诊断前10年处方药使用。IBD人群在14个ATC主要药物类别中的12类普遍用药更多,CD尤为显著,诊断前2年多个器官系统用药陡增,提示IBD存在多器官受累。

要点

  • IBD诊断前10年,14个ATC主要药物类别中12类的使用者比例较匹配人群高1.1至1.8倍(P<0.0001)。
  • 诊断前10年,CD人群免疫抑制剂、抗贫血制剂、镇痛药、精神抑制药使用者分别为匹配人群的2.7、2.3、1.9、1.9倍(P<0.0001)。
  • 诊断前2年,IBD人群多个器官系统用药出现陡增。

核心结论

  • IBD诊断前数年即普遍存在用药增加,CD尤为明显,提示IBD涉及多器官受累。

研究设计与样本

  • 基于丹麦全国关联登记数据的匹配研究,纳入2005至2018年确诊的29219例IBD患者,匹配292190例无IBD个体。
  • 主要结局为IBD诊断/匹配日期前1至10年任何处方药的使用;诊断/匹配前领取至少1次世界卫生组织解剖治疗化学(ATC)主要类别或亚组药物处方者定义为用药者。

主要发现

  • 诊断前10年,IBD人群在14个ATC主要药物类别中的12类使用者比例较匹配人群高1.1至1.8倍(P<0.0001)。
  • 该差异见于各年龄、性别和IBD亚型,以克罗恩病(CD)最为明显。
  • 诊断前2年,IBD人群多个器官系统的用药陡增。
  • 诊断前10年,CD人群免疫抑制剂、抗贫血制剂、镇痛药、精神抑制药使用者分别为匹配人群的2.7、2.3、1.9、1.9倍(P<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is growing interest in the prediagnostic phase of inflammatory bowel disease (IBD) and in the overlap of IBD with other diseases. We described and compared use of any prescription medication between individuals with and without IBD in a 10-year period preceding diagnosis. METHODS: Based on cross-linked nationwide registers, we identified 29,219 individuals diagnosed with IBD in Denmark between 2005 and 2018 and matched to 292,190 IBD-free individuals. The primary outcome was use of any prescription medication in years 1-10 before IBD diagnosis/matching date. Participants were considered as medication users if they redeemed ≥1 prescription for any medication in the World Health Organization Anatomical Therapeutic Chemical (ATC) main groups or subgroups before diagnosis/matching. RESULTS: The IBD population had a universally increased use of medications compared with the matched population before IBD diagnosis. At 10 years before diagnosis, the proportion of users was 1.1-fold to 1.8-fold higher in the IBD population in 12 of 14 ATC main groups of medication ( P -value < 0.0001). This applied across age, sex, and IBD subtypes, although it was the most pronounced for Crohn's disease (CD). Two years before diagnosis, the IBD population had a steep increase in medication use for several organ systems. When analyzing therapeutic subgroups of medication, the CD population exhibited 2.7, 2.3, 1.9, and 1.9 times more users of immunosuppressants, antianemic preparations, analgesics, and psycholeptics, respectively, than the matched population 10 years before diagnosis ( P -value < 0.0001). DISCUSSION: Our findings demonstrate universally increased medication use years before IBD, especially CD, diagnosis and indicates multiorgan involvement in IBD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Bonfils L, Karachalia Sandri A, Poulsen GJ, et al. Medication-Wide Study: Exploring Medication Use 10 Years Before a Diagnosis of Inflammatory Bowel Disease. Am J Gastroenterol. 2023. PMID: 37410928. doi:10.14309/ajg.0000000000002399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。